Next Generation Personalized Neuroblastoma Therapy
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 83
Summary
- Conditions
- Cancer
- Neuroblastoma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 1 years and 21 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02780128
- Collaborators
- Novartis Pharmaceuticals
- Foundation Medicine
- Investigators
- Principal Investigator: Yael P Mossé, MD Children's Hospital of Philadelphia, The University of Pennsylvania Principal Investigator: John M Maris, MD Children's Hospital of Philadelphia, The University of Pennsylvania